Data from EAU Highlight Superior Patient Experience and Benefits of Early Intervention1-3

Matt Ashley, MD
Associate Medical Director
Teleflex Interventional Urology

Our team has just returned from a successful European Association of Urology (EAU) Congress in Milan, where we were excited to see new research presented on the UroLift® System. While reinforcing the positive impacts it has on the patient experience, the results also underscore the benefits of early intervention with respect to quality of life improvement and sexual function** that urologists around the world have come to expect from the UroLift® System1. Please click here to find the press release recently issued by Teleflex.

Importantly, the new analysis presented at EAU builds on the more than 145 peer-reviewed and 22 sponsored publications that reinforce the UroLift® System as a BPH solution that meets patient needs. Insightful research data presented highlight the durability of the UroLift System with more to be featured at the upcoming AUA Annual Meeting. Among the new studies were two of particular interest to me which show that, compared to other interventions, the UroLift® System offers unique benefits for the treatment of BPH. Key findings from these two studies are:

Earlier BPH treatment in the disease continuum (e.g., better IPSS and quality of life [QoL] scores at baseline) positively impacts quality of life outcomes. Similarly, treatment with the UroLift® System prior to severe erectile dysfunction in sexually active patients predicts the likelihood of a patient achieving meaningful change, as revealed in the Sexual Health Inventory for Men (SHIM) assessment.1 These results are from more than 330 PUL subjects treated in a controlled setting.1,2

UroLift® System obstructive median lobe (OML) and lateral lobe patients responded consistently in a responder analysis utilizing the novel BPH6 study composite endpoint (relief of symptoms, quality of recovery, preservation of sexual function, preservation of continence, and safety).*3 Compared to TURP done in lateral lobes, UroLift® System OML subjects achieved superior quality of recovery and preservation of ejaculatory function. Additionally, only these TURP subjects experienced high-severity postoperative adverse events.3

The results from these studies emphasize the value of the UroLift® System in:

  • Successfully treating BPH symptoms1-3
  • Enabling rapid recovery1-3
  • Preserving sexual function^1-3
  • Providing a superior patient experience
  • Improving patients’ overall quality of life1-3

New and meaningful quality of life data analyses clearly support the benefits of earlier intervention. It’s time we change our patients’ journeys with confidence.  

References

* Individual elements of the BPH6 composite endpoint assessed the following: 1) LUTS improvement; 2) Quality of Recovery; 3) Preservation of Erectile function; 4) Preservation of Ejaculatory function; 5) Continence preservation; and 6) Safety

** likelihood of a patient achieving meaningful change, as revealed in the Sexual Health Inventory for Men (SHIM) assessment

^No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study

1. Barber, et al, EAU 2023. Patient characteristics and dynamic variables predictive of meaningful quality of life and sexual function improvement after Prostatic Urethral Lift (PUL). [Conference Presentation] Study sponsored by Teleflex Incorporated or its affiliates.

2. Roehrborn, et al, EAU 2023. Durability following treatment with the Prostatic Urethral Lift (PUL): Predictors from over 330 controlled subjects across 5 distinct studies. [Conference Presentation] Study sponsored by Teleflex Incorporated or its affiliates.

3. Eure, et al, EAU 2023. Patient experience outcomes are consistent between men with median and lateral lobe obstruction following treatment with the Prostatic Urethral Lift (PUL). [Conference Presentation] Study sponsored by Teleflex Incorporated or its affiliates. 4 Roehrborn, J Urology 2013

 

 MAC02677-01 Rev A